Pulmotect
Pulmotect is focused on developing inhaled therapeutics that stimulate the innate immune system in the lungs to provide rapid protection against respiratory pathogens. The company's clinical-stage approach targets a broad set of at-risk populations, including those with chronic respiratory diseases and immunocompromised patients, aiming to reduce respiratory complications such as pneumonia.
Industries
Nr. of Employees
small (1-50)
Pulmotect is currently seeking investment
Pulmotect is seeking a series-b investment in the range of 1m-5m
Patents
Products
An inhaled therapeutic designed to stimulate the lung's innate immune system, offering immediate protection against a variety of respiratory pathogens. Assessed in several early-stage trials for safety, tolerability, and efficacy in both healthy and at-risk populations.
An inhaled therapeutic designed to stimulate the lung's innate immune system, offering immediate protection against a variety of respiratory pathogens. Assessed in several early-stage trials for safety, tolerability, and efficacy in both healthy and at-risk populations.
Expertise Areas
- Clinical trial management
- Respiratory therapeutics development
- Innate immune stimulation
- Immunocompromised patient care
Key Technologies
- Inhaled immune stimulants
- Innate immunity activation
Key People
Colin Broom, MD
CEO
Brenton Scott, PhD
COO
Colin Broom, MD
CEO
Brenton Scott, PhD
COO
News & Updates
Received $7.1 million in funding to develop a novel inhaled immune stimulant for respiratory protection.
Received $7.1 million in funding to develop a novel inhaled immune stimulant for respiratory protection.